At your institution, do you experience any significant barriers to having prescriptions authorized for alirocumab or evolocumab? And how have the price reductions affected either your perception of, access to, and/or reimbursement for these agents?

Name: At your institution, do you experience any significant barriers to having prescriptions authorized for alirocumab or evolocumab? And how have the price reductions affected either your perception of, access to, and/or reimbursement for these agents?
Uploaded: 2019-03-11T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Samuel Goldhaber, MD

Section Head, Vascular Medicine
Director, Thrombosis Research Group
Cardiovascular Medicine
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA USA